- Details
- Gerhardt Attard joins Charles Ryan to discuss the optimal steroid and dose to be given with abiraterone for the management of castration-resistant prostate cancer (CRPC). The two review the risks and benefits of either the standard dose of 5mg prednisone BID compared to a lower steroid dose of 5mg daily. Dr. Attard also shares his perspective on using dexamethasone, which has also shown to have an...
|
- Details
- Justin Drake, University of Minnesota, discusses the latest and ongoing research associated with the correlation between RET gene expression and neuroendocrine prostate cancer. The recent data shows enhanced RET gene expression in patients that have this AR negative neuroendocrine positive phenotype. Drake also highlighted his work in the development of noninvasive ways of detecting RET signaling...
|
- Details
- Phuoc Tran, Johns Hopkins University, provides an overview of several ongoing clinical trials for prostate cancer. SALV-ENZA is a Phase II randomized placebo-controlled trial of salvage radiation, which then randomizes to either to placebo or the oral next-generation antiandrogen drug known as enzalutamide. Dr. Tran also reviews the ORIOLE and RAVENS clinical trials which examine metastasis-direct...
|
- Details
- Neal Shore and Bertrand Tombal discuss the importance of bone health agents, particularly in patients receiving castrate-resistant prostate cancer agents. Highlights of their conversation include the use of antiresorptive therapy to reduce the risk of skeletal-related events in men with bone mCRPC and decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial. Bi...
|
- Details
- Scott Tagawa joins Alicia Morgans at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) and discusses advances in bladder and prostate cancer. He highlights his recent work on antibody-drug conjugates (ADCs) specifically, sacituzumab govitecan in metastatic urothelial cancer and the and the initial results from TROPHY-U-01. Although immune checkpoint inhibitors now provide an...
|
- Details
- In this conversation, Alicia Morgans and Cora Sternberg, Medical Oncologist and Clinical Director of the Englander Institute for Precision Medicine, Weill Cornell Medicine in New York discuss the recently presented results from the CARD trial. The CARD Trial a phase 4 clinical trial compared cabazitaxel vs abiraterone or enzalutamide in patients who were previously treated with docetaxel and had p...
|
- Details
- At the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019), Charles Ryan is joined by his colleague Aaron Le Beau from the University of Minnesota who specializes in the developments of targeted imaging agents and therapeutics for prostate cancer using novel antibody constructs. Drs. Ryan and LeBeau discuss the work he is doing on potential alternate targets to PSMA. Antibodies we...
|
- Details
- Alexander Wyatt from the University of British Columbia joins Charles Ryan at the 26th Annual Prostate Cancer Foundation Scientific Retreat (PCF 2019) to talk about the current state of cell-free DNA and what a clinician can use in the treatment of prostate cancer from cell-free DNA for current testing. Biographies: Alexander Wyatt, Ph.D., BSc, Assistant Professor, Department of Urologic Sciences,...
|
- Details
- Akash Patnaik, an Assistant Professor of Medicine at the University of Chicago joins Alicia Morgans to speak about his work and expertise with immunotherapy in prostate cancer. Dr. Patnaik and Dr. Morgans discuss the work that he is doing in the lab to better understand why some patients have exceptional responses to combining two different immunotherapies targeting CTLA-4 and PD-1 in prostate can...
|
- Details
- Bertrand Tombal presents the recently published results from the CARD trial: "CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent". Enzalutamide in Metastatic Prostate Cancer (mCRPC) is highly heterogeneous with the coe...
|
